ZYME Stock: Price, Earnings History and SEC Filings
Zymeworks Inc. (ZYME) last traded at $28.61, down 0.35% on the latest session and up 8.0% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-0.62 against an analyst estimate of $-0.56, a miss of 10.7%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
ZYME earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 6, 2026 | $-0.62 | $-0.56 | -10.71% |
| Mar 2026 | May 7, 2026 | $-0.59 | $-0.10 | -490.00% |
| Dec 2025 | Mar 2, 2026 | $-0.55 | $-0.35 | -57.14% |
| Sep 2025 | Nov 6, 2025 | $-0.26 | $-0.30 | +13.33% |
ZYME beat the analyst EPS estimate in 1 of its last 4 reported quarters. Source: Nasdaq.
How ZYME reacts to earnings
Across its last 8 earnings releases, ZYME moved 4.1% on average the next session, in either direction. It rose after 3 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-06 | After close | +1.77% |
| 2026-05-07 | After close | -10.19% |
| 2026-03-02 | Before open | +0.09% |
| 2026-01-12 | After close | +3.28% |
| 2025-11-06 | After close | -8.04% |
| 2025-08-07 | After close | -1.15% |
| 2025-05-08 | After close | -0.13% |
| 2025-03-05 | After close | -7.97% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
ZYME financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $106M | -$81M | -$35M | -76.6% | $-1.08 |
| 2024 | $76M | -$123M | -$112M | -160.8% | $-1.62 |
| 2023 | $76M | -$119M | -$121M | -156.1% | $-1.72 |
| 2022 | $412M | $124M | $136M | 30.1% | $1.90 |
| 2021 | $27M | -$212M | -$205M | -794.0% | $-4.61 |
| 2020 | $39M | -$181M | -$156M | -463.5% | $-3.58 |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for ZYME
- DEF 14A · Oct 26, 2026
- 8-K · Oct 23, 2026Material agreement, Regulation FD disclosure, Financial statements and exhibits
- 8-K · Sep 23, 2026Material agreement, Acquisition or disposal completed, New financial obligation
- 8-K · Aug 25, 2026Regulation FD disclosure, Other events, Financial statements and exhibits
- 10-Q · Aug 6, 2026
- 8-K · Aug 6, 2026Results of operations, Regulation FD disclosure, Financial statements and exhibits
- 8-K · Jun 29, 2026Material agreement, Regulation FD disclosure, Financial statements and exhibits
- 8-K · May 14, 2026Regulation FD disclosure, Other events, Financial statements and exhibits
- 10-Q · May 7, 2026
- 8-K · May 7, 2026Results of operations, Regulation FD disclosure, Financial statements and exhibits
Insider filing activity
ZYME insiders filed 1 Form 4 report in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
ZYME news
- Zymeworks Inc. (ZYME) to Report Q3 Results: Wall Street Expects Earnings GrowthOct 29, 2026 · finance.yahoo.com
- Zymeworks Highlights ZW191 Ovarian Cancer Responses, Roche Deal UpsideOct 27, 2026 · marketbeat.com
- Faeth Appoints Adam Schayowitz, Ph.D., MBA, Head of Research and Development at Zymeworks, to Board of DirectorsOct 27, 2026 · finance.yahoo.com
- How Investors Are Reacting To Zymeworks (ZYME) Roche Licensing DealOct 26, 2026 · finance.yahoo.com
- Another autoimmune CAR-T death; Treasury zeroes in on China dealsOct 26, 2026 · biopharmadive.com
- Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026Oct 24, 2026 · finance.yahoo.com
- Zymeworks Announces Global DLL3 T-Cell Engager PartnershipOct 24, 2026 · theglobeandmail.com
- Stocktwits Biotech Dealmaker: Gilead And Roche Double Down On Early-Stage Assets Over Full Buyouts This WeekOct 24, 2026 · stocktwits.com
About Zymeworks Inc.
Zymeworks Inc. (ZYME) is a US-listed public company on Nasdaq. The SEC classifies its business as Pharmaceutical Preparations. It is incorporated in DE. Its fiscal year ends in December.